AIDS Treatment News logo      

June 14, 2009

New drug for MDR-TB does well in trial

"TMC207 is a safe and effective drug for the treatment of multidrug-resistant tuberculosis (TB), the results of a randomised, placebo-controlled trial published in the June 4th edition of the New England Journal of Medicine have shown. Patients who received the drug were significantly more likely to have a negative culture result after eight weeks than patients who received standard second-line TB treatment."

Read more in Aidsmap, June 9, 2009 [restored].